Pharmacology and Analytical Facility - HPLC and Mass Spectrometry FacilityThis facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and massspectrometry instruments. In this facility, analytical assay methodologies can be developed and validatedusing UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiodearray, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instrumentsinclude a simple single quad LC/MS instrument for use in molecular weight determinations as well as morecomplex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drugmetabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MSinstrument is available for separation and quantitation of volatile compounds. Recently added wereautomated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest(drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organtissues, and tumors). These extraction systems have improved both extraction efficiency and throughput inanalytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug libraryscreening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification,drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility andstability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysisincreased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52faculty members who are members of 21 CCSG Programs; 90% of the users have peer-reviewed funding.The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located ata newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLCsystems. In addition to the advanced analytical facility the combined program faculty have in excess of 60years of experience in analytical chemistry, analytical method development and validation, isolationtechnologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as aninvaluable resource in experimental design, development and implementation to the user faculty who oftenlack the specific training to conduct experiments requiring quantitative analytical chemistry andpharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-33
Application #
7695942
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-28
Project End
2013-06-30
Budget Start
2008-08-28
Budget End
2009-06-30
Support Year
33
Fiscal Year
2008
Total Cost
$297,221
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Hui, David; Hess, Kenneth; Dibaj, Seyedeh S et al. (2018) The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer 124:2246-2252
LeBleu, Valerie S; Kalluri, Raghu (2018) A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Saltz, Joel; Gupta, Rajarsi; Hou, Le et al. (2018) Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23:181-193.e7
Dondossola, Eleonora; Alexander, Stephanie; Holzapfel, Boris M et al. (2018) Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10:
Yue, Jinbo; Shi, Qiuling; Xu, Ting et al. (2018) Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27:1563-1570
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240

Showing the most recent 10 out of 12418 publications